Navigation Links
Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
Date:2/4/2008

ncer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
3. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
5. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
6. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Access Pharmaceuticals Announces $2.7 Million New Equity
8. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
9. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
10. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
11. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... prefer to settle into equilibriuma state of unchanging ... realm of non-equilibrium conditions where new possibilities lie. ... phases, such as temperature fluctuations, freezing and melting, ... their body temperature, airplanes to fly, and the ... But even though these conditions exist naturally and ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Genomics and Proteomics Analytical Instruments Market 2014-2018" report ... Genomics is the study of the ... of the structure and functions of proteomes or sets ... and technology. Genomics involves the mapping of genes and ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) ... in the HIV-1 therapeutic space, announced today a ... Institute (NCI) to further the development of the ... inhibitors are a novel class of antiretroviral drug ...
... of California, Riverside engineering professor and a team of ... material that could play a major role in keeping ... Balandin, a professor of electrical engineering at the UC ... University of Texas at Austin, The University of Texas ...
... by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the ... combination of Equity, and Debt Conversion. ... Biologics. After completing the acquisition of the Global ... early last year, Pinnacle continues the process of ...
Cached Biology Technology:DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs 3Keeping electronics cool 2Keeping electronics cool 3Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round 2Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round 3
(Date:7/25/2014)... the first time, Spanish researchers have detected an unknown ... cells are introduced into a droplet of salt ... sodium chloride crystallisation to create biomineralogical biosaline 3D morphologically ... the material, bacteria are revived. The discovery was made ... the cover of the Astrobiology journal and ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... on average over a 35 year period in which ... impact of humans on declining animal numbers. This decline ... insects, spiders, crustaceans, slugs and worms bring to our ... decomposition for nutrient cycling, water filtration and human health. ... led by UCL, Stanford and UCSB, focused on the ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... CAAugust 14, 2011Scientists at the Gladstone Institutes have gained new ... out of balance, can prevent the normal development of stem ... some types of cancer. "The news, being announced in ... , adds to the understanding of the role of stem ...
... Extinction is a focal issue among scientists, policy makers ... are thought to have disappeared are rediscovered. Yet, these ... from the National University of Singapore (NUS), University of ... 122 years, at least 351 species which are thought ...
... the direct impact of fishing as the largest known ... sea lion population. The team,s findings, published in ... and identifies resource competition and by-catch incidents as the ... Phocarctos hookeri is the country,s only native pinniped species ...
Cached Biology News:Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 2Gladstone scientists offer new insight into the regulation of stem cells and cancer cells 3Rediscovery of disappeared species: Truly back from the brink? 2Competition with humans responsible for decline of New Zealand's endangered sea lions, study shows 2
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
...
Biology Products: